Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: AnchorDx | Guangzhou Baseline Medical | AnchorDx Medical Co.Ltd | AnchorDx, Inc. | AnchorDx, Inc | AnchorDx Inc | AnchorDx Inc. | AnchorDx Corp. | AnchorDx Medical Co. Ltd. | AnchorDx Corp
Related tests:


IVD丨China’s first urothelial cancer auxiliary diagnostic kit (UriFind®) has been approved for marketing (AnchorDx Press Release)
" ...the 'Human ONECUT2/VIM Gene Methylation Detection Kit (Fluorescent PCR Method)' (hereinafter referred to as UriFind®) independently developed and produced by Guangzhou Benchmark Medical Co., Ltd. has obtained the National Medical Products Administration (NMPA) III Medical device registration certificate (National Medical Device Approval No. 20243400221)."
Non-US regulatory
UriFind® Methylation Test
AnchorDx, DiaCarta partner to advance cancer screening tests (Genomeweb)
"AnchorDx said Monday that it has entered into a long-term collaboration with DiaCarta aimed at product development and global commercialization in the cancer screening space...Under the agreement, AnchorDx and DiaCarta will leverage proprietary technologies for DNA methylation and mutation detection that each company has developed...The firm is currently conducting a registrational and prospective clinical trial for the urine-based assay, dubbed UriFind, and Pleasanton, California-based DiaCarta will serve as one of the clinical testing laboratories."
Licensing / partnership
UriFind® Methylation Test
AnchorDx Enrolls the First Patient For Its UriFind® bladder cancer assay clinical trial in the U.S. (BioSpace)
"AnchorDx...announced the first patient enrollment for the UriFind® bladder cancer assay clinical trial in the U.S., an over 1,000-patient multi-center, prospective testing of the assay in the targeted patients. This prospective, registrational study is aimed to evaluate the performance of the non-invasive, quantitative real-time PCR (qPCR) assay designed to detect two DNA methylation biomarkers in urine specimens from patients suspected of having bladder cancer."
Enrollment status
UriFind® Methylation Test
AnchorDx receives CE Mark for lung cancer early diagnosis test (Genomeweb)
"AnchorDx said Wednesday that its PulmoSeek lung cancer early detection assay, has received CE marking, with a reagents license issued by the Netherlands' CIBG of Ministry of Health, Welfare, and Sport."
European regulatory
PulmoSeek Lung Cancer Early Detection Assay